↑Campoli-Richards DM, Todd PA (August 1987). "Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use". Drugs. 34 (2): 188–221. doi:10.2165/00003495-198734020-00002. PMID3304966.
↑US 4098888,Ochiai M, Okada T, Aki O, Morimoto A, Kawakita K, Matsushita Y,"Thiazolylacetamido cephalosporin type compounds",issued 7 April 1978, assigned to Takeda Pharmaceutical Co Ltd.
Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, etal. (May 1995). "[Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis]". The Japanese Journal of Antibiotics. 48 (5): 602–609. PMID7637194.
Paladino JA, Fell RE (March 1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia". The Annals of Pharmacotherapy. 28 (3): 384–389. doi:10.1177/106002809402800316. PMID8193431. S2CID29444681.
Duncker GI, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262–266. doi:10.1159/000310505. PMID7816419.